vs
Side-by-side financial comparison of ASTRONICS CORP (ATRO) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $240.1M, roughly 1.2× ASTRONICS CORP). On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 15.1%). ASTRONICS CORP produced more free cash flow last quarter ($15.8M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 13.9%).
Astronics Corporation is an American aerospace electronics corporation founded in 1968, headquartered in East Aurora, New York. It is traded on NASDAQ as Nasdaq: ATRO. It is known for lighting and electronics integrations on military, commercial, and business aircraft and semiconductor test systems.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
ATRO vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $240.1M | $281.3M |
| Net Profit | — | $-128.5M |
| Gross Margin | 33.3% | 64.6% |
| Operating Margin | 14.8% | -43.0% |
| Net Margin | — | -45.7% |
| Revenue YoY | 15.1% | 39.4% |
| Net Profit YoY | — | -15.8% |
| EPS (diluted) | $0.82 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $240.1M | $281.3M | ||
| Q3 25 | $211.4M | $265.2M | ||
| Q2 25 | $204.7M | $232.1M | ||
| Q1 25 | $205.9M | $203.5M | ||
| Q4 24 | $208.5M | $201.8M | ||
| Q3 24 | $203.7M | $191.5M | ||
| Q2 24 | $198.1M | $177.2M | ||
| Q1 24 | $185.1M | $168.5M |
| Q4 25 | — | $-128.5M | ||
| Q3 25 | $-11.1M | $-92.7M | ||
| Q2 25 | $1.3M | $-99.9M | ||
| Q1 25 | $9.5M | $-95.2M | ||
| Q4 24 | — | $-111.0M | ||
| Q3 24 | $-11.7M | $-107.8M | ||
| Q2 24 | $1.5M | $-102.6M | ||
| Q1 24 | $-3.2M | $-115.0M |
| Q4 25 | 33.3% | 64.6% | ||
| Q3 25 | 30.5% | 64.7% | ||
| Q2 25 | 25.8% | 65.0% | ||
| Q1 25 | 29.5% | 63.3% | ||
| Q4 24 | 29.8% | 61.6% | ||
| Q3 24 | 27.1% | 61.1% | ||
| Q2 24 | 28.0% | 59.1% | ||
| Q1 24 | 25.7% | 61.2% |
| Q4 25 | 14.8% | -43.0% | ||
| Q3 25 | 10.9% | -37.3% | ||
| Q2 25 | 2.3% | -45.9% | ||
| Q1 25 | 6.4% | -54.6% | ||
| Q4 24 | 4.3% | -62.4% | ||
| Q3 24 | 4.1% | -61.3% | ||
| Q2 24 | 3.8% | -56.8% | ||
| Q1 24 | 0.9% | -59.2% |
| Q4 25 | — | -45.7% | ||
| Q3 25 | -5.2% | -35.0% | ||
| Q2 25 | 0.6% | -43.0% | ||
| Q1 25 | 4.6% | -46.8% | ||
| Q4 24 | — | -55.0% | ||
| Q3 24 | -5.8% | -56.3% | ||
| Q2 24 | 0.8% | -57.9% | ||
| Q1 24 | -1.7% | -68.2% |
| Q4 25 | $0.82 | $-1.01 | ||
| Q3 25 | $-0.31 | $-0.74 | ||
| Q2 25 | $0.04 | $-0.80 | ||
| Q1 25 | $0.26 | $-0.77 | ||
| Q4 24 | $-0.07 | $-0.90 | ||
| Q3 24 | $-0.34 | $-0.88 | ||
| Q2 24 | $0.04 | $-0.84 | ||
| Q1 24 | $-0.09 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.2M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $140.1M | $-99.3M |
| Total Assets | $706.7M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $378.2M | ||
| Q3 25 | $13.5M | $580.0M | ||
| Q2 25 | $13.5M | $629.1M | ||
| Q1 25 | $24.8M | $698.6M | ||
| Q4 24 | $9.3M | $525.5M | ||
| Q3 24 | $5.2M | $585.0M | ||
| Q2 24 | $2.9M | $933.7M | ||
| Q1 24 | $5.3M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $140.1M | $-99.3M | ||
| Q3 25 | $108.9M | $-354.5M | ||
| Q2 25 | $271.6M | $-305.5M | ||
| Q1 25 | $266.8M | $-250.8M | ||
| Q4 24 | $256.1M | $-139.6M | ||
| Q3 24 | $249.2M | $-60.1M | ||
| Q2 24 | $257.9M | $-1.6M | ||
| Q1 24 | $251.7M | $68.3M |
| Q4 25 | $706.7M | $2.0B | ||
| Q3 25 | $682.2M | $1.3B | ||
| Q2 25 | $646.7M | $1.3B | ||
| Q1 25 | $662.2M | $1.3B | ||
| Q4 24 | $648.8M | $1.5B | ||
| Q3 24 | $651.6M | $1.5B | ||
| Q2 24 | $644.9M | $1.6B | ||
| Q1 24 | $630.0M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.6M | $-26.4M |
| Free Cash FlowOCF − Capex | $15.8M | $-54.2M |
| FCF MarginFCF / Revenue | 6.6% | -19.3% |
| Capex IntensityCapex / Revenue | 4.9% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.6M | $-26.4M | ||
| Q3 25 | $34.2M | $-35.4M | ||
| Q2 25 | $-7.6M | $-60.3M | ||
| Q1 25 | $20.6M | $-62.7M | ||
| Q4 24 | $26.4M | $-64.5M | ||
| Q3 24 | $8.4M | $-51.1M | ||
| Q2 24 | $-6.3M | $-94.0M | ||
| Q1 24 | $2.0M | $-30.3M |
| Q4 25 | $15.8M | $-54.2M | ||
| Q3 25 | $21.0M | $-45.8M | ||
| Q2 25 | $-12.2M | $-65.9M | ||
| Q1 25 | $18.5M | $-67.1M | ||
| Q4 24 | $23.2M | $-83.4M | ||
| Q3 24 | $6.5M | $-55.3M | ||
| Q2 24 | $-8.1M | $-99.1M | ||
| Q1 24 | $439.0K | $-37.2M |
| Q4 25 | 6.6% | -19.3% | ||
| Q3 25 | 9.9% | -17.3% | ||
| Q2 25 | -6.0% | -28.4% | ||
| Q1 25 | 9.0% | -33.0% | ||
| Q4 24 | 11.1% | -41.3% | ||
| Q3 24 | 3.2% | -28.9% | ||
| Q2 24 | -4.1% | -55.9% | ||
| Q1 24 | 0.2% | -22.1% |
| Q4 25 | 4.9% | 9.9% | ||
| Q3 25 | 6.2% | 3.9% | ||
| Q2 25 | 2.2% | 2.4% | ||
| Q1 25 | 1.0% | 2.2% | ||
| Q4 24 | 1.5% | 9.4% | ||
| Q3 24 | 0.9% | 2.2% | ||
| Q2 24 | 0.9% | 2.9% | ||
| Q1 24 | 0.9% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -5.81× | — | ||
| Q1 25 | 2.17× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.08× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRO
| Product Line Electrical Power And Motion | $113.8M | 47% |
| Product Line Avionics | $32.0M | 13% |
| Military Aircraft | $28.0M | 12% |
| General Aviation | $22.3M | 9% |
| Government And Defense | $20.5M | 9% |
| Product Line Systems Certification | $13.2M | 6% |
| Product Line Structures | $3.7M | 2% |
| Product Line Other | $2.3M | 1% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
